

Date:11.11.2022

To,

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 11.11.2022

Ref: Company's Letter dated 01.11.2022

Unit: Trimurthi Limited

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Trimurthi Limited** at its meeting held on Friday, the 11th day of November 2022 at 11:00A.M. at the registered office of the Company situated at 5-8-354/1106, Office No. 1106, Ratna Block, Raghav Ratna Towers, Chirag Ali Lane, Hyderabad - 500001, Telangana, approved the following:

1. Unaudited financial results (both standalone and consolidated) for the quarter and half year ended 30.09.2022. **(Enclosed)**
2. Limited Review Report (both standalone and consolidated) as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the Quarter and half year ended 30.09.2022. **(Enclosed)**

This is for the information and records of the Exchange, please.

The meeting concluded at 1:30 p.m.

Thanking you.

For Trimurthi Limited



Arun Kumar Bhangadia
Chairman and Managing Director
DIN: 00021024

ARUN
KUMAR
BHANGADIA

Digitally signed
by ARUN KUMAR
BHANGADIA
Date: 2022.11.11
13:34:54 +05'30'

Encl. as above

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED

354/1106, Office No. 1106
Raghav Ratna Block,
Chirag Ali Lane, Abid
Hyderabad, Telangana - 500 001

TRIMURTHI LIMITED
4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095.
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS
FOR THE QUARTER II AND HALF YEAR ENDED 30th SEPTEMBER 2022

PARTICULARS	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED (AUDITED)
	30.09.2022 (UNAUDITED)	30.06.2022 (UNAUDITED)	30.09.2021 (UNAUDITED)	30.09.2022 (UNAUDITED)	30.09.2021 (UNAUDITED)	
I. INCOME						
INCOME FROM OPERATIONS	4.77	6.67	20.39	11.24	67.81	94.32
OTHER INCOME	4.42	3.03	29.73	10.05	39.50	55.17
TOTAL INCOME	9.19	9.70	50.12	21.29	107.31	150.49
II. EXPENSES						
PURCHASES	3.18	3.75	18.48	6.89	97.23	139.79
COST OF MATERIALS CONSUMED						
MANUFACTURING EXPENSES						
INCREASE/(DECREASE) IN STOCK IN TRADE	0.75	0.20	(0.27)	0.35	(0.63)	(28.37)
RENT	0.09		0.26	0.90	0.60	2.13
EMPLOYEE BENEFITS EXPENSE	7.07	6.76	6.38	13.87	12.90	29.11
FINANCE COSTS	-		-			
DEPRECIATION AND AMORTISATION EXPENSES	1.03	0.71	0.51	1.74	2.12	7.24
OTHER EXPENSES	4.24	6.92	7.41	12.31	12.40	176.88
TOTAL EXPENSES	17.14	17.95	23.11	35.58	93.05	296.07
III. PROFIT/(LOSS) FROM BEFORE EXCEPTIONAL ITEMS AND TAX (I-II)	(7.95)	(8.80)	27.21	(33.79)	14.21	(156.59)
IV. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS						
V. PROFIT/(LOSS) FROM CONTINUING OPERATIONS BEFORE TAX	(7.95)	(8.80)	27.21	(33.79)	14.21	(156.59)
VI. TAX EXPENSES						
CURRENT TAX	0.55	0.21	6.21	0.34	6.20	(0.54)
TAX ADJUSTMENT IN RELATING TO earlier TRADE DEFERRED TAX (NET)	-		3.99			
DEFERRED TAX (NET)	0.55	0.21	2.02	0.34	2.01	0.00
VII. NET PROFIT/(LOSS) FROM CONTINUING OPERATIONS AFTER TAX (V-I)	6.50	(8.04)	21.00	(34.13)	8.10	(156.09)
VIII. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS						
IX. TAX EXPENSES FOR DISCONTINUED OPERATIONS						
X. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS AFTER TAX (V-I)						
XI. PROFIT/(LOSS) FOR THE PERIOD (V+X)	6.50	(8.04)	21.00	(34.13)	8.10	(156.09)
XII. OTHER COMPREHENSIVE INCOME						
LOSS						
(i) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS						
(ii) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS						
(iii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS						
XIII. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (XI+XII) (COMPRISING PROFIT/(LOSS) AND OTHER COMPREHENSIVE INCOME)	6.50	(8.04)	21.00	(34.13)	8.10	(156.09)
XIV. EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION):						
(i) BASIC	(0.10)	(0.07)	0.28	(0.17)	0.10	(1.99)
(ii) DILUTED	(0.10)	(0.07)	0.28	(0.17)	0.10	(1.99)
XV. EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION):						
(i) BASIC						
(ii) DILUTED						
XVI. EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION):						
(i) BASIC	(0.35)	(0.07)	0.28	(0.17)	0.10	(1.99)
(ii) DILUTED	(0.35)	(0.07)	0.28	(0.17)	0.10	(1.99)

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956


TRIMURTHI LIMITED
554/1106, Chirag 1106/1106,
Block, Raghav Ratna Towers,
Chirag Ali Lane, Abid,
Hyderabad - 500 001



TRIMURTHI LIMITED

TRIMURTHI
GROUP

PARTICULARS	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED (AUDITED)
	30/09/2022 (UNAUDITED)	30/06/2022 (UNAUDITED)	30/09/2021 (UNAUDITED)	30/09/2022 (UNAUDITED)	30/09/2021 (UNAUDITED)	
A. PARTICULARS OF SHARE HOLDING						
1. Public Share Holding						
- Number of Shares	267927	267927	267927	267927	267927	267927
- Percentage of shareholding	33.08%	33.08%	33.08%	33.08%	33.08%	33.08%
2. Proprietor and promoter group shareholding						
a. Fledged / encumbered						
- No. of Equity Shares	751	751	751	751	751	751
- Percentage of Shares (of the shareholding of promoter and	751	751	751	751	751	751
- Percentage of Shares (of the total share capital of the company)	751	751	751	751	751	751
b. Non-encumbered						
- No. of Equity Shares	342273	342273	342273	342273	342273	342273
- Percentage of Shares (of the shareholding of promoter and	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	99.92%	99.92%	99.92%	99.92%	99.92%	99.92%

Particular	3 Months Ended 30/09/2022
ii. Investor Complaint	
Pending at the beginning of the quarter	NIL
Received during the quarter	NIL
Disposed during the quarter	NIL
Remaining unresolved during the quarter	NIL

TRIMURTHI LIMITED

Segment Reporting

PARTICULARS	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED (AUDITED)
	30/09/2022 (UNAUDITED)	30/06/2022 (UNAUDITED)	30/09/2021 (UNAUDITED)	30/09/2022 (UNAUDITED)	30/09/2021 (UNAUDITED)	
i. Segment Revenue						
a. Pharma Business	1.13	1.13	-	2.65	-	8.75
b. Financial Services	4.80	5.03	4.38	10.05	14.12	29.78
c. Investments	0.02	-	25.38	0.02	25.38	0.50
d. Trading in Shares	3.21	5.38	20.59	8.59	87.81	100.62
e. Trade						-
Total	9.19	12.33	80.32	21.29	107.31	139.49
Less: Inter Segment Revenue						
Net Sales/ Income From Operations	9.19	12.33	80.32	21.29	107.31	139.49
ii. Segment Profit (Before tax & Interest From Each Segment)						
a. Pharma Business	1.39	0.38	-	1.39	-	-
b. Financial Services	4.40	5.63	4.34	10.09	14.12	15.05
c. Investments	0.02	-	25.38	0.02	25.38	108.54
d. Trading in Shares	(11.77)	(11.62)	(2.52)	(25.39)	(25.16)	(22.09)
e. Trade						
Total	(7.96)	(8.83)	27.29	(33.79)	14.31	(136.56)
Less:						
i. Interest						
ii. Other Un-Attributable expenses (as per)						
iii. Un-allowable Income						
Total Profit Before Tax	(7.96)	(8.83)	27.29	(33.79)	14.31	(136.56)
iii. Capital Employed						
a. Pharma Business	70.36	70.47	29.59	70.36	29.50	29.50
b. Financial Services	90.41	102.13	314.93	90.41	104.45	301.65
c. Investments	281.20	263.20	29.32	201.20	29.32	49.92
d. Trading in Shares	338.38	343.88	214.67	338.38	214.67	349.25
e. Trade	-	-	300.39	-	300.39	-
Total	711.35	718.27	888.48	712.35	888.48	734.30

Status

- Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 11-11-2022.
- The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34-Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.
- The results are also available on the website of the Company.

Place: Hyderabad
Date: 13-11-2022

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email: info@trimurthidrugs.com
Website: www.trimurthidrugs.com
CIN No: L67120TG1994PLC018956

V. Kumar
TRIMURTHI LIMITED
354/1106, Office No. 1106,
Block, Raghav Ratna Towers,
Chirag Ali Lane, Abid,
Hyderabad, Telangana - 500 001.



TRIMURTHI
GROUP

Notes

- 1 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- 2 The unaudited consolidated financial results for the quarter ended 30th, 2022 have been reviewed by the Audit committee and approved by the board of Directors at its meeting held on 13-11-2022 and have been subjected to limited review by the statutory auditors of the company. The Consolidated Financial results are prepared in accordance with the Indian accounting standards (Ind AS) as prescribed under section 133 of Companies Act,2013.
- 3 The results are also available on the website of the Company.



Place: Hyderabad
Date: 13-11-2022



TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/A8C, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email: info@trimurthidrugs.com
Website: www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

MURTHI LIMITED

54/1106, Office No. 1106,
Block, Raghav Ratna Tower
Chirag Ali Lane, Abid,
Hyderabad, Telangana - 500 001.

TRIMURTHI LIMITED
4-4-231/1/2/ABC Inder Bagh, Sultan Bazar, Hyderabad - 500095.
STANDALONE BALANCE SHEET AS AT 30-09-2022



PARTICULARS	Figures as at	Figures as at
	30-09-2022	31-03-2022
ASSETS:		
A. Non Current Assets		
(a) Property, Plant and Equipment	20,85,923	22,60,284
(b) Capital Work In Progress		
(c) Investment Property	1,73,87,962	1,73,87,962
(d) Other Intangible Assets	102	102
(e) Financial Assets		
(i) Investments	58,82,000	58,82,000
(ii) Trade Receivables		
(iii) Loans		
(iv) Other Financial Assets		
(f) Deferred Tax Assets (Net)	8,27,418	8,80,984
(g) Other Non Current Assets		-
B. Current Assets		
(a) Inventories	52,64,139	53,19,140
(b) Financial Assets		
(i) Investments		
(ii) Trade Receivables	8,98,449	9,98,056
(iii) Cash & Cash Equivalents	2,59,32,340	2,60,49,225
(iv) Bank Balances other than (ii) above		
(v) Short Term Loans and Advances	99,41,157	1,09,17,536
(vi) Others	31,15,929	30,36,800
TOTAL ASSETS	7,31,35,417	7,25,12,084
EQUITY AND LIABILITIES:		
A. Equity		
(a) Equity Share Capital	8,10,00,000	8,10,00,000
(b) Other Equity	(99,81,977)	(85,69,445)
B. Non Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings		
(ii) Trade Payables		
(iii) Other Financial Liabilities		
(b) Provisions		
(c) Deferred Tax Liabilities (Net)		
(d) Other Non Current Liabilities		-
B. Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings		
(ii) Trade Payables	1,16,332	-
(iii) Other Financial Liabilities		
(b) Other Current Liabilities	1,062	30,499
(c) Provisions		
(d) Current Tax Liabilities (Net)	-	-
TOTAL EQUITY AND LIABILITIES	7,31,35,417	7,25,12,084
Significant Accounting Policies and Notes to Accounts		

Place: Hyderabad
 Date: 11-11-2022

For Trimurthi Limited

From the Manager
 Arun Kumar Mitalia
 Managing Director
 DIN No. 00221024



TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
 4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
 Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
 Email: info@trimurthidrugs.com
 Website: www.trimurthidrugs.com
 CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED

304/1106, Office No. 1106,
 Block, Raghav Raina Towers,
 Chirag Ali Lane, Abid,
 Hyderabad, Telangana - 500 071



TRIMURTHI
GROUP

TRIMURTHI LIMITED

4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad-500095.

STANDALONE CASH FLOW STATEMENT FOR THE PERIOD ENDED 30th Sep 2022

Particulars	As at 30-09-2022	As at 31-03-2022
A. Cash Flow from Operating Activities:		
Net Profit before Tax and Extraordinary Items	(15,78,966)	(1,36,57,977)
Adjustments for:		
Depreciation	1,24,362	7,36,375
Interest & Other Income	(10,05,182)	(55,36,918)
Loss on Sale of Fixed Assets	-	2,25,833
Loss on Sale of Investments & Property	-	1,50,03,000
Profit on sale of mutual funds	-	(55,161)
Operating profit before Working Capital Changes	(22,09,787)	(32,64,847)
Adjustments for:		
Trade and Other receivables	20,445	1,41,91,574
Inventories	55,001	(28,37,221)
Trade & Other payables	10,13,273	(1,59,866)
Cash generated from Operations	10,87,719	1,71,94,487
Cash flow before Extraordinary Items	(11,22,060)	59,29,440
Extraordinary Items and Tax	-	-
Net Cash used for Operating activities	(11,22,060)	59,29,440
B. Cash Flow from Investing Activities:		
Purchase of Fixed Assets		(1,86,47,830)
Sale of Fixed Assets		1,95,000
Capital Work in progress		
Sale of Investments		1,55,82,161
Increase / (Decrease) in Security Deposits		
Interest & Other Income	10,05,182	55,36,918
Net Cash flow from Investing activities	10,05,182	27,33,249
C. Cash Flow from Financing Activities:		
Increase in Share Capital	-	-
Increase in Share Premium	-	-
Increase / Decrease in Long Term Borrowings	-	-
Share Issue and Preliminary Expenses	-	-
Dividends Paid	-	-
Net Cash flow from Financing activities		
Net Increase in Cash and Cash Equivalents	(1,16,880)	86,80,889
Cash and Cash Equivalents as of (Opening Balance)	2,66,49,225	173,68,337
Cash and Cash Equivalents as at (Closing Balance)	2,59,32,339	260,49,226

For Trimurthi Limited

Arun Kumar Bhagadaria
Managing Director
DIN No. 00021024



Place: Hyderabad
Date: 13-11-2022

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED

354/1106, Office No. 1106,
1st Block, Raghav Ratna Tower
Chirag Ali Lane, Abids,
Hyderabad, Telangana - 500 00



TRIMURTHI LIMITED
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER II AND HALF YEAR ENDED 30TH SEPTEMBER 2022

TRIMURTHI
GROUP

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2022 (UNAUDITED)	30.06.2022 (UNAUDITED)	30.09.2021 (UNAUDITED)	30.09.2022 (UNAUDITED)	30.09.2021 (UNAUDITED)	
I. Income From Operations						
Net Sales / Income From Operations	129.86	135.97	209.26	260.06	481.11	846.85
Other Income	5.49	5.64	29.28	11.33	36.34	55.41
II. Total Income	129.86	141.60	209.26	271.39	481.11	816.26
III. Expenses						
(a) Consumption of Raw Material	1.63	1.66	4.66	14.29	34.82	36.77
(b) Purchase of Trade Goods / Stores	39.87	31.74	101.87	210.11	426.14	826.63
(c) (In respect) Decrease in Stock to Trade and work in Progress	2.75	(9.28)	(5.20)	0.55	(91.46)	(20.57)
(d) Manufacturing Expenses						
(e) Employment / Rent expenses	19.70	14.13	33.51	33.63	35.14	71.96
(f) Rent	3.74		1.70	3.74	2.00	8.20
(g) Finance Costs						
(h) Depreciation	1.99	1.66	3.68	3.65	8.34	10.20
(i) Other Expenses	4.83	12.82	12.73	16.73	28.78	213.06
Total	145.56	132.51	234.73	295.89	490.33	1126.81
IV. Profit / (Loss) Before Exceptional items and Tax (II-III)	(15.69)	(88.70)	81.27	(24.59)	30.00	(232.16)
V. Exceptional Items/Prior Period Items						
VI. Profit / (Loss) Before Tax & Share in Associate (IV-V)	(13.69)	(88.70)	81.27	(24.59)	30.00	(232.16)
VII. Share of Profit/Loss of Associate	(1.27)	3.82	3.58	0.33	9.36	8.67
VIII. Profit/Loss Before Tax (V-VII)	(13.96)	(86.88)	81.25	(24.26)	39.37	(233.49)
IX. Tax expense:						
(1) Current tax	0.27	0.36	0.56	0.62	12.94	6.76
(2) Deferred tax						
X. Net Profit / (Loss) for the period (item continuing operations) (VIII-IX)	(15.39)	(86.28)	81.29	(24.39)	27.43	(202.71)
XI. Profit/(Loss) From discontinued operations						
XII. Tax expense of discontinued operations						
XIII. Profit/(Loss) From Discontinued operations (after tax) (X-XII)						
XIV. Profit/(Loss) for the period (X+XIII)	(15.39)	(86.28)	81.29	(24.39)	27.43	(202.71)
XV. Other Comprehensive Income						
(a) (i) Items that will not be reclassified to profit or loss						
(i) Income tax relating to items that will not be reclassified to profit or loss						
(b) (ii) Items that will be reclassified to profit or loss						
(ii) Income tax relating to items that will be reclassified to profit or loss						
XVI. Total Comprehensive Income for the period (XIV+XV) (including Profit /Loss and Other comprehensive income for the period)	(15.39)	(91.24)	81.29	(24.39)	27.43	(202.71)
XVII. Minority Interest	(2.46)	(2.06)	1.20	(4.32)	16.20	(22.46)
XVIII. Total Comprehensive Income for the period after Minority Interest (XVI-XVII)	(12.93)	(71.18)	81.29	(28.71)	17.13	(180.92)
XIX. Earnings per equity share (for continuing operations):						
(1) Basic	0.19	(0.11)	0.39	(0.30)	0.21	(0.22)
(2) Diluted	0.19	(0.11)	0.39	(0.30)	0.21	(0.22)
XX. Earnings per equity share (for discontinued & continuing operations):						
(1) Basic	0.19	0.10	0.39	(0.30)	0.21	(0.22)
(2) Diluted	0.19	0.10	0.39	(0.30)	0.21	(0.22)
XXI. Earnings per equity share (for discontinued & continuing operations):						
(1) Basic	0.19	0.10	0.39	(0.30)	0.21	(0.22)
(2) Diluted	0.19	0.10	0.39	(0.30)	0.21	(0.22)



TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email: info@trimurthidrugs.com
Website: www.trimurthidrugs.com
CIN No: L67120TG1994PLC018956

TRIMURTHI LIMITED

354/1106, Office No. 1106,
Jewel Block, Raghav Retail Tower,
Chinag Ali Lane, Abid,
Hyderabad, Telangana - 500 034.



TRIMURTHI LIMITED

TRIMURTHI

Particulars	Quarter Ended			Half Year Ended		
	30.09.2022 (UNAUDITED)	30.06.2022 (UNAUDITED)	30.09.2021 (UNAUDITED)	30.09.2022 (UNAUDITED)	30.06.2022 (UNAUDITED)	31.12.2021 (AUDITED)
1. Particulars Of Share Holding						
1. Public Share Holding						
i. Number of Shares	2679367	2679367	2679367	2679367	2679367	2679367
ii. Percentage of shareholding	33.08%	33.08%	33.08%	33.08%	33.08%	33.08%
2. Promoter and promoter group shareholding						
a. Displed, Encumbered						
b. Net of equity shares	-	-	-	-	-	-
c. Percentage of shares of the shareholding of promoter and promoter group	-	-	-	-	-	-
d. Percentage of shares of the total share capital of the company	-	-	-	-	-	-
3. Non-encumbered						
i. Net of equity shares	5420731	5420731	5420731	5420731	5420731	5420731
ii. Percentage of shares of the shareholding of promoter and promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
iii. Percentage of shares of the total share capital of the company	46.92%	46.92%	46.92%	46.92%	46.92%	46.92%
4. Particulars	6 Months Ended (30.06.2022)					
5. Investor Complaints	Nil					
i. Pending at the beginning of the quarter	Nil					
ii. Received during the quarter	Nil					
iii. Disposed during the quarter	Nil					
iv. Remaining pending at the end of the quarter	Nil					

TRIMURTHI LIMITED

Segment Reporting:

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2022 (UNAUDITED)	30.06.2022 (UNAUDITED)	30.09.2021 (UNAUDITED)	30.09.2022 (UNAUDITED)	30.06.2021 (UNAUDITED)	
1. Segment Revenue						
a. Pharma Business	121.90	129.40	107.54	221.47	132.11	78.46
b. Financial Services	5.40	5.04	4.74	11.36	18.11	29.78
c. Investments	0.00	23.40	0.00	25.40	25.39	0.00
d. Trade	-	-	28.02	80.00	0.00	-
e. Trading in Shares	2.31	6.87	20.59	8.26	67.01	75.62
Total	129.79	141.40	275.96	271.36	220.55	916.25
Less: Inter Segment Revenue						
Net Sales/ Income From Operations	129.79	141.40	275.96	271.36	220.55	916.25
2. Segment Profit (Before Tax & Interest From Each Segment)						
a. Pharma Business	(2.01)	(8.43)	10.43	(10.46)	30.62	(3.27)
b. Financial Services	5.66	5.84	4.35	11.70	14.09	15.39
c. Investments	0.07	0.00	35.40	0.02	25.40	0.55
d. Trade	0.00	0.00	5.82	(11.11)	(20.18)	-
e. Trading in Shares	(17.49)	(27.91)	(27.52)	(25.39)	(25.19)	(204.67)
Total	(13.80)	(30.71)	41.27	(24.54)	30.00	(212.14)
Less:						
i. Interest	-	-	-	-	-	-
ii. Other Un-allocable expenses net of	-	-	-	-	-	-
iii. Unallocable Income	-	-	-	-	-	-
Total Profit Before Tax	(13.80)	(30.71)	41.27	(24.54)	30.00	(212.14)
3. Capital Employed						
a. Pharma Business	148.94	104.99	153.42	148.94	153.42	77.55
b. Financial Services	17.59	0.00	215.32	17.59	215.32	255.88
c. Investments	216.30	211.37	56.38	216.30	36.50	35.96
d. Trade	0.00	0.00	63.63	-	63.63	74.07
e. Trading in Shares	337.21	416.36	214.67	337.21	214.67	298.64
Total	720.33	731.22	763.80	720.33	705.40	746.40

TRIMURTHI LIMITED
Arun Kumar

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED
354/1106, Office No. 1106,
Block, Raghav Ratna Towers,
Chirag Ali Lane, Abid,
Hyderabad, Telangana - 500 001.



TRIMURTHI
GROUP

TRIMURTHI LIMITED

Registered Office : 4-4-231/1/2, Inderbagh, Sultanbazar, Hyderabad-500009.

CONSOLIDATED BALANCE SHEET AS AT 30-09-2022

PARTICULARS	Figures for the period ended	Figures for the year ended
	30-09-2022	31-03-2022
ASSETS		
A. Non Current Assets		
(i) Property, Plant and Equipment	42,64,872	42,30,032
(ii) Capital Work In Progress	-	-
(iii) Investment Property	1,73,87,962	1,71,87,962
(iv) Other Intangible Assets	70,216	1,06,084
(v) Financial Assets	-	-
(i) Investments	42,13,220	42,13,220
(ii) Trade Receivables	-	-
(iii) Loans	-	-
(iv) Other Financial Assets	-	-
(vi) Deferred Tax Assets (Net)	5,30,785	8,32,081
(vii) Other Non Current Assets	21,56,000	11,30,000
	-	-
B. Current Assets		
(i) Inventories	84,79,721	90,63,779
(ii) Financial Assets	-	-
(i) Investments	-	-
(ii) Trade Receivables	1,29,84,738	1,21,13,463
(iii) Cash & Cash Equivalents	2,74,91,419	2,80,96,951
(iv) Bank Balances other than (ii) above	-	-
(v) Short Term Loans and Advances	32,06,620	45,67,535
(vi) Others (to be specified)	36,87,465	39,68,495
	-	-
TOTAL ASSETS	8,45,28,479	8,73,77,515
EQUITY AND LIABILITIES		
A. Equity		
(i) Equity Share Capital	8,10,00,000	8,10,00,000
(ii) Other Equity	40,23,386	40,34,429
	-	-
B. Non Controlling Interest	22,63,984	
C. Non Current Liabilities		
(i) Financial Liabilities	-	-
(ii) Borrowings	-	-
(iii) Trade Payables	-	-
(iv) Other Financial Liabilities	-	-
(ii) Provisions	-	-
(iii) Deferred Tax Liabilities (Net)	-	-
(iv) Other Non Current Liabilities	-	-
	-	-
D. Current Liabilities		
(i) Financial Liabilities	-	-
(ii) Borrowings	16,45,732	16,45,037
(iii) Trade Payables	88,17,209	88,25,516
(iv) Other Financial Liabilities	-	-
(ii) Other Current Liabilities	4,030	1,21,034
(iii) Provisions	-	-
(iv) Current Tax Liabilities (Net)	-	-
	-	-
TOTAL EQUITY AND LIABILITIES	8,45,28,479	8,73,77,515

For Trimurthi Limited -

Amit Kumar Bhagat
Managing Director
DIN No. 00021894

Place: Hyderabad
Date: 31-10-2022

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)

4-4-231/1/2/ABC, Inderbagh, Sultanbazar,

Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email : info@trimurthidrugs.com

Website : www.trimurthidrugs.com

CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED

4/1106, Office No. 1106,

Block, Ranjiv Ratna Towers,

Chirag Ali Lane, Abid,

Hyderabad, Telangana - 500 051



TRIMURTHI LIMITED

TRIMURTHI
GROUP

4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad-500095.

CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 30th SEP, 2022

Particulars	As at 30.09.2022	As at 31.03.2022
A. Cash Flow from Operating Activities:		
Net Profit before Tax and Extraordinary Items	-2451146.907	(2,12,15,784)
Adjustments for:		
Depreciation	364840.267	10,19,793
Interest & Other Expense		
Interest & Other Income		(35,16,918)
Miscellaneous Exp Write off		
(Profit)/Loss on Sale of Assets		2,25,830
(Profit)/Loss on Sale of Investments		1,50,03,000
(Profit)/Loss on Sale of Investments		(35,161)
Operating profit before Working Capital Changes	(20,86,287)	(1,05,19,236)
Adjustments for:		
Trade and Other receivables	-69,436.18	1,34,43,135
Inventories	14,6078.26	(30,07,990)
Trade payables	-33,4573.75	93,08,024
Other Assets	243,744.78	(11,38,000)
Cash generated from Operations	7,23,913	1,88,93,169
Cash flow before Extraordinary Items	(13,62,374)	73,73,933
Extraordinary Items and Tax		
Net Cash used for Operating activities	(13,62,374)	73,73,933
B. Cash Flow from Investing Activities:		
Purchase of Fixed Assets	-43,172.58	(2,07,08,906)
Sale of Fixed Assets		3,00,000
Purchase of Investments		
Sale of Investments		1,54,19,107
Interest & Other Income		55,16,918
Net Cash flow from Investing activities	(43,173)	5,27,118
C. Cash Flow from Financing Activities:		
Increase in Share Capital	-Nil-	-Nil-
Increase in Share Premium	-Nil-	-Nil-
Increase / Decrease in Long Term Borrowings	-Nil-	-Nil-
Share Issue and Preliminary Expenses	-Nil-	-Nil-
Dividends Paid	-Nil-	-Nil-
Capital Contribution from Minority Interest	-Nil-	-Nil-
Net Cash flow from Financing activities	-	-
Net Increase in Cash and Cash Equivalents	(34,05,546)	81,01,851
Cash and Cash Equivalents as at (Opening Balance)	2,88,96,950	2,07,93,899
Cash and Cash Equivalents as at (Closing Balance)	2,74,91,404	2,88,96,950

Place: Hyderabad
Date: 11-11-2022

For Trimurthi Limited

Arun Kumar Shahrukh
Managing Director
DIN No. 00023828

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED

354/1106, Office No. 1106,
a Block, Raghav Ratna Towers,
Chirag Ali Lane, F-14
Hyderabad, Telangana - 500003



P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review report to
The Board of Directors
Trimurthi Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **TRIMURTHI LIMITED** (the "Company") for the quarter ended 30 September, 2022 and for the period from 01 April 2022 to 30 September 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34,') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants
FRN: 007257S


A.Krishna Rao
Partner
M.No. 020085
UDIN: 22020085BCUITL4936

Place: Hyderabad
Date: 11/11/2022



P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review report to
The Board of Directors
Trimurthi Limited

We have reviewed the accompanying statement of unaudited consolidated financial results of **Trimurthi Limited** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") it's Associate for the quarter ended 30 September, 2022 and for the period from 01 April 2022 to 30 September 2022 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

1. Trimurthi Pharmaceuticals(India) Private Limited - Subsidiary
2. Curova India LLP - Associate

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:

Associate, whose interim Financial Statements reflect Group's share of total net profit of Rs.55,221/- for the Half Year ended 30th September, 2022 as considered in the consolidated Financial Results. These unaudited interim Financial Statements have been furnished to us by the management and our conclusion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of this associate is based solely on such unaudited interim Financial Statements/financial information. In our opinion and according to the information and explanations given to us by the Board of Directors, these interim Financial Statements /financial information are not material to the Group.





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

Our conclusion on the Statement in respect of matters stated above is not modified
with respect to our reliance on the financial results certified by the Management

For P. Murali & Co.

Chartered Accountants

FRN: 007257S

A.Krishna Rao

Partner

M.No. 020085

UDIN: 22020085BCVJIM7131

Place: Hyderabad

Date: 11/11/2022

